DeCure's autonomous Cancer AI scientist is researching a drug-repurposing hypothesis for Malignancy in Giant Cell Tumor of Bone — screening already-approved drugs against its 13-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleMalignancy in Giant Cell Tumor of Bone maps to a 13-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for malignancy in giant cell tumor of bone is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
fibroblast growth factor receptor 4 (FGFR4) — FGFR4 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet 1~{r}drag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 8KH8 · 1.49 Å · ligand 1-[4-[(1~{R})-1-[3,5-bis(chloranyl)pyridin-4-yl]ethoxy]-5-cyano-pyridin-2-yl]-3-[6-methanoyl-5-[(4-methyl-2-oxidanylidene-piperazin-1-yl)methyl]-3-(2-morpholin-4-ylethoxy)pyridin-2-yl]urea (VVW). Experimental structure, not a prediction.
What the evidence adds up to
The 1951 paper states that confusion about what constitutes genuine giant-cell tumour of bone has vitiated most treatment reports from the preceding decade. The author calls for accurate pathological diagnosis before any treatment and for well-controlled, long-range clinical experiments, possibly through a tumour registry, to produce data for a sound therapeutic programme.
A 2019 retrospective study of 25 patients (16 female, 9 male, mean age 34.5 years) reports that giant cell tumour of bone is benign but aggressive. Twenty-three patients received treatment; 15 of those had intralesional curettage with or without adjuvants, and seven had wide excision. Recurrence occurred in 45% (9 of 20) of primary tumours, especially in difficult anatomical locations, and most recurrences happened more than four years after treatment. Pulmonary nodules were detected in four patients; two resolved during follow-up. One patient developed secondary sarcoma transformation with a fatal outcome. The authors note that denosumab can be used for pulmonary metastasis, multicentric, and recurrent disease.
A 2023 case report describes a rare maxillary giant cell tumour with pulmonary and calvarial metastasis in a young female patient. The report states that the recurrence rate for giant cell tumour of bone is between 40% and 60%, and that 5% to 7% of recurrent cases are malignant. Craniofacial involvement accounts for only 2% of cases.
What is still missing is the registry and controlled long-range clinical experiments called for in 1951, which have not been established. The available data come from small retrospective series and single case reports. No randomised trial has compared curettage, wide excision, or denosumab in a stratified patient population. The timing and criteria for using denosumab remain undefined, and the optimal duration of follow-up to detect late recurrence and malignant transformation is not established.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Journal of Bone and Joint Surgery · 1951 · 36 citations
GIANT-CELL TUMOR OF BONE
AbstractThe uncertainty that still prevails in many quarters as to what should properly be regarded as giant-cell tumor of bone (stripped of its spurious variants) has had the effect of vitiating most of the contributions to the literature of the past ten years. This confusion must be dispelled before reports in regard to the efficacy of treatment, by one method or another, are to have much significance. To this end, the writer has outlined some of the pertinent advances of the past decade concerning the clinical and pathological features of genuine giant-cell tumor and of certain other lesions which are frequently mistaken for it. The necessity for establishing accurate pathological diagnosis before instituting treatment, whether surgical or irradiation, has again been emphasized. In regard to therapy, the writer has tried to survey some of the specific problems entailed in the treatment, by either method, of a giant-cell tumor that is approached for the first time, and of one that has already recurred after treatment. Significant progress in the solution of these problems can only come about through the effective planning, possibly through the agency of a giant-cell-tumor registry, of well controlled, long-range clinical experiments that alone can supply the data upon which a sound therapeutic program must eventually be based.
Giant cell tumor of bone: Unusual features of a rare tumor
AbstractGiant cell tumor of bone is a benign tumor with an aggressive behavior. Its typical subarticular location and high recurrence risk can be associated with significant morbidity. Although benign, it can rarely metastasize especially to the lungs. Also, it can be multicentric in less than 1% of patients. Late malignant transformation, although rare, can occur with a very poor prognosis. This series reports on these unusual and challenging features and management considerations of giant cell tumor of bone. This retrospective study included review of the medical records of patients with a confirmed histopathological diagnosis of giant cell tumor of bone. A total of 25 patients (16 females and 9 males) with a mean age of 34.5 years were included; 22 had primary tumors, while 3 were referred with recurrent tumors. Pain was the most common presenting symptom. Most patients had grade III tumors. Tumors around the knee were the most common. Multicentric tumors were detected in three patients. Twenty-three patients (20 primary giant cell tumor of bone and 3 with recurrence) received treatment. Most patients (15/23) were treated with intralesional curettage with or without adjuvants. Seven patients had wide excision. Recurrence was seen in 45% (9/20) of primary giant cell tumor of bone especially with difficult anatomical locations. Most recurrences occurred more than 4 years after treatment. Pulmonary nodules were detected in four patients; two of them showed resolution during follow-up. One patient developed secondary sarcoma transformation with a fatal outcome. Giant cell tumor of bone was more common in females. Long bones were more affected, especially around the knee. Intralesional curettage was the most frequently used treatment. Recurrence was associated with inadequate tumor resection (especially in difficult anatomical location), younger age, male gender, and advanced local tumor grade. Denosumab can be used in the treatment of pulmonary metastasis, multicentric and recurrent giant cell tumor of bone. Due to late recurrence and malignant transformation, a prolonged follow-up is warranted.
International Journal of Applied Dental Sciences · 2023 · 0 citations · open access
A rare case of maxillary osteoclastoma with pulmonary and calvarial metastasis
AbstractAn uncommon, benign, locally aggressive osteolytic neoplasm called a giant cell tumor (also known as an osteoclastoma or myeloid sarcoma) of the bone typically affects matured long bones and accounts for 5 to 9% of all primary bone tumours. It mainly targets the epiphysis of long bones. Most often benign, they rarely spread to the lungs. The treatment plan usually ranges from simple curettage to wide resection, with typically a good prognosis. The recurrence rate has been reported to be between 40% and 60% and 5% to 7% of recurrent cases are malignant. However, such tumor growth is rarely encountered in craniofacial bones like the temporal, ethmoid, sphenoid, maxilla, and mandible which accounts only for 2% of cases. Herein this article we present and discuss the clinical presentation, radiological features, histopathological investigations, treatment procedures and follow-ups done in such a rare case of giant cell tumor involving maxilla in a young female patient.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
